



- (51) **International Patent Classification:**
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)
- (21) **International Application Number:**
PCT/EP2012/065906
- (22) **International Filing Date:**
14 August 2012 (14.08.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
- | | | |
|------------|-----------------------------|----|
| 11177658.9 | 16 August 2011 (16.08.2011) | EP |
| 61/523,861 | 16 August 2011 (16.08.2011) | US |
| 61/647,539 | 16 May 2012 (16.05.2012) | US |
| 61/654,097 | 1 June 2012 (01.06.2012) | US |
- (71) **Applicant** (for all designated States except US):
MORPHOSYS AG [DE/DE]; Lena-Christ-Strasse 48,
82152 Martinsried/Planegg (DE).


- (72) **Inventors; and**
- (75) **Inventors/Applicants** (for US only): **AMERSDORFER, Jutta** [DE/DE]; Lena-Christ-Str. 48, 82152 Martinsried / Planegg (DE). **STEIDL, Stefan** [DE/DE]; Ebenböckstr. 25, 81241 München (DE). **WINDERLICH, Mark** [DE/DE]; Implersstr. 52, 81371 München (DE). **KROHN, Susanne** [DE/DE]; Haidelweg 22a, 81241 München (DE). **ROJKJAER, Lisa** [CA/CH]; Frohmoosstrasse 38h, CH-8908 Hedingen (CH).
- (74) **Agent:** **HUTTER, Bernd**; Lena-Christ-Str. 48, 82152 Planegg-Martinsried (DE).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

[Continued on next page]

- (54) **Title:** COMBINATION THERAPY WITH AN ANTI - CD19 ANTIBODY AND A NITROGEN MUSTARD

Figure 5

Normalized specific killing; SD; MEC-1 target cells pretreated with Bendamustine (Ben) for 48 h before ADCC; pool of 3 independent experiments with 3 different effector cell donors



The figure shows the averages from the data shown in Table 2.

- (57) **Abstract:** The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.



SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

COMBINATION THERAPY WITH AN ANTI - CD19 ANTIBODY AND A NITROGEN MUSTARD

Cross reference

This application claims the benefit of U.S. provisional application serial number 61/654,097 filed June 1, 2012, U.S. provisional application serial number 61/647,539 filed May 16, 2012, and U.S. provisional application serial number 61/523,861 filed August 16, 2011, which are incorporated by reference in their entireties.

Field of the Invention

The present disclosure is related to a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

Background

B cells are lymphocytes that play a large role in the humoral immune response. They are produced in the bone marrow of most mammals, and represent 5-15% of the circulating lymphoid pool. The principal function of B cells is to make antibodies against various antigens, and are an essential component of the adaptive immune system.

Because of their critical role in regulating the immune system, dysregulation of B cells is associated with a variety of disorders, such as lymphomas, and leukemias. These include non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).

NHL is a heterogeneous malignancy originating from lymphocytes. In the United States (U.S.), the incidence is estimated at 65,000/year with mortality of approximately 20,000 (American Cancer Society, 2006; and SEER Cancer Statistics Review). The disease can occur in all ages, the usual onset begins in adults over 40 years, with the incidence increasing with age. NHL is characterized by a clonal proliferation of lymphocytes that accumulate in the lymph nodes, blood, bone marrow and spleen, although any major organ may be involved. The current classification system used by pathologists and clinicians is the World Health Organization (WHO) Classification of Tumours, which organizes NHL into precursor and mature B-cell or T-cell neoplasms. The PDQ is currently dividing NHL as indolent or aggressive for entry into clinical trials. The indolent NHL group is comprised primarily of follicular subtypes, small lymphocytic lymphoma, MALT (mucosa-associated lymphoid tissue), and marginal zone; indolent encompasses approximately 50% of newly diagnosed B-cell NHL patients. Aggressive NHL includes patients with histologic diagnoses of primarily diffuse large B cell (DLBL, DLBCL, or DLCL) (40% of all newly diagnosed patients have diffuse large cell), Burkitt's, and mantle cell. The clinical course of NHL is highly variable. A major determinant of

clinical course is the histologic subtype. Most indolent types of NHL are considered to be incurable disease. Patients respond initially to either chemotherapy or antibody therapy and most will relapse. Studies to date have not demonstrated an improvement in survival with early intervention. In asymptomatic patients, it is acceptable to "watch and wait" until the patient becomes symptomatic or the disease pace appears to be accelerating. Over time, the disease may transform to a more aggressive histology. The median survival is 8 to 10 years, and indolent patients often receive 3 or more treatments during the treatment phase of their disease. Initial treatment of the symptomatic indolent NHL patient historically has been combination chemotherapy. The most commonly used agents include: cyclophosphamide, vincristine and prednisone (CVP); or cyclophosphamide, adriamycin, vincristine, prednisone (CHOP). Approximately 70% to 80% of patients will respond to their initial chemotherapy, duration of remissions last on the order of 2-3 years. Ultimately the majority of patients relapse. The discovery and clinical use of the anti-CD20 antibody, rituximab, has provided significant improvements in response and survival rate. The current standard of care for most patients is rituximab + CHOP (R-CHOP) or rituximab + CVP (R-CVP). Interferon is approved for initial treatment of NHL in combination with alkylating agents, but has limited use in the U.S. Rituximab therapy has been shown to be efficacious in several types of NHL, and is currently approved as a first line treatment for both indolent (follicular lymphoma) and aggressive NHL (diffuse large B cell lymphoma). However, there are significant limitations of anti-CD20 monoclonal antibody (mAb), including primary resistance (50% response in relapsed indolent patients), acquired resistance (50% response rate upon re-treatment), rare complete response (2% complete response rate in relapsed population), and a continued pattern of relapse. Finally, many B cells do not express CD20, and thus many B-cell disorders are not treatable using anti-CD20 antibody therapy.

In addition to NHL there are several types of leukemias that result from dysregulation of B cells. Chronic lymphocytic leukemia (also known as "chronic lymphoid leukemia" or "CLL"), is a type of adult leukemia caused by an abnormal accumulation of B lymphocytes. In CLL, the malignant lymphocytes may look normal and mature, but they are not able to cope effectively with infection. CLL is the most common form of leukemia in adults. Men are twice as likely to develop CLL as women. However, the key risk factor is age. Over 75% of new cases are diagnosed in patients over age 50. More than 10,000 cases are diagnosed every year and the mortality is almost 5,000 a year (American Cancer Society, 2006; and SEER Cancer Statistics Review). CLL is an incurable disease but progresses slowly in most cases. Many people with CLL lead normal and active lives for many years. Because of its slow onset, early-stage CLL is generally not treated since it is believed that early CLL intervention does not improve survival time or quality of life. Instead, the condition is monitored over time. Initial CLL treatments vary depending on the exact diagnosis and the progression of the disease. There are dozens of agents used for CLL therapy. Combination chemotherapy regimens

such as FCR (fludarabine, cyclophosphamide and rituximab), and BR (bendamustine and rituximab) are effective in both newly-diagnosed and relapsed CLL. Allogeneic bone marrow (stem cell) transplantation is rarely used as a first-line treatment for CLL due to its risk.

Another type of leukemia is acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia. ALL is characterised by the overproduction and continuous multiplication of malignant and immature white blood cells (also known as lymphoblasts) in the bone marrow. 'Acute' refers to the undifferentiated, immature state of the circulating lymphocytes ("blasts"), and that the disease progresses rapidly with life expectancy of weeks to months if left untreated. ALL is most common in childhood with a peak incidence of 4-5 years of age. Children of age 12- 16 die more easily from it than others. Currently, at least 80% of childhood ALL are considered curable. Under 4,000 cases are diagnosed every year and the mortality is almost 1,500 a year (American Cancer Society, 2006; and SEER Cancer Statistics Review).

The human CD 19 molecule is a structurally distinct cell surface receptor expressed on the surface of human B cells, including, but not limited to, pre-B cells, B cells in early development (i.e., immature B cells), mature B cells through terminal differentiation into plasma cells, and malignant B cells. CD 19 is expressed by most pre-B acute lymphoblastic leukemias (ALL), non-Hodgkin's lymphomas, B cell chronic lymphocytic leukemias (CLL), pro-lymphocytic leukemias, hairy cell leukemias, common acute lymphocytic leukemias, and some Null-acute lymphoblastic leukemias (Nadler et al, J. Immunol., 131 :244-250 (1983), Loken et al, Blood, 70:1316-1324 (1987), Uckun et al, Blood, 71 :13- 29 (1988), Anderson et al, 1984. Blood, 63:1424-1433 (1984), Scheuermann, Leuk. Lymphoma, 18:385-397(1995)). The expression of CD 19 on plasma cells further suggests it may be expressed on differentiated B cell tumors such as multiple myeloma, plasmacytomas, Waldenstrom's tumors (Grossbard et al., Br. J. Haematol, 102:509- 15(1998); Treon et al, Semin. Oncol, 30:248-52(2003)).

Therefore, the CD 19 antigen is a target for immunotherapy in the treatment of non-Hodgkin's lymphoma (including each the subtypes described herein), chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

Certain CD19 therapies have been shown. T cells expressing an anti-CD19 chimeric antigen receptor (CAR) including both CD3- ζ and the 4-1BB costimulatory domain were administered to three patients with advanced CLL. Kalos et al., T cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia, Science Translational Medicine, vol. 3, no. 95 (10 August 2011), which is incorporated by reference in its entirety. Sadelain et al., The promise and potential pitfalls of chimeric antigen receptors, Current Opinion in Immunology, Elsevier, vol. 21, no.2, 2 April 2009, which is incorporated by reference in its entirety, also describes anti-CD19 chimeric antigen receptors (CARs). Neither Kalos et al. nor

Sadelain et al., however, describe the antibody specific for CD19 in combination with bendamustine as exemplified herein.

Bendamustine as a therapy in the treatment of non-hodgkin's lymphoma was described in Bremer et al., High rates of long lasting remission after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's lymphomas, Journal of Cancer Research and Clinical Oncology, Springer International, Berlin, DE, vol. 128, no. 11, 1 November 2002, which is incorporated by reference in its entirety, and WO2006065392, which is incorporated by reference in its entirety, but neither suggests the antibody specific for CD19 in combination with bendamustine as exemplified herein.

The use of a CD19 antibody in non-specific B cell lymphomas is discussed in WO2007076950 (US2007154473), which are both incorporated by reference in their entireties, along with the cursory mention of bendamustine within a long list of potential combination partners, but fails either to teach the antibody exemplified herein or suggest the synergistic effects of the combination in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia as exemplified herein.

The use of a CD19 antibody in CLL, NHL and ALL is described in Scheuermann et al., CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy, Leukemia and Lymphoma, Vol. 18, 385-397 (1995), which is incorporated by reference in its entirety, but fails to suggest the combination exemplified herein.

Additional antibodies specific for CD19 are described in WO2005012493 (US7109304), WO2010053716 (US12/266,999) (Immunomedics); WO2007002223 (US US8097703) (Medarex); WO2008022152 (12/377,251) and WO2008150494 (Xencor), WO2008031056 (US11/852,106) (Medimmune); WO 2007076950 (US 11/648,505) (Merck Patent GmbH); WO 2009/052431 (US12/253,895) (Seattle Genetics); and WO2010095031 (12/710,442) (Glenmark Pharmaceuticals), which are all incorporated by reference in their entireties.

Combinations of antibodies specific for CD19 and other agents are described in WO2010151341 (US 13/377,514) (The Feinstein Institute); US5686072 (University of Texas), and WO2002022212 (PCT/US01/29026) (IDEC Pharmaceuticals), which are all incorporated by reference in their entireties.

It is clear that in spite of the recent progress in the discovery and development of anti-cancer agents, many forms of cancer involving CD19-expressing tumors still have a poor prognosis. Thus, there is a need for improved methods for treating such forms of cancer.

Summary

Neither alone nor in combination does the prior art suggest the synergistic effects of the combination of the exemplified antibody and bendamustine in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

In one aspect, the present disclosure relates to a synergistic combination of an antibody specific for CD19 and a nitrogen mustard. Such combinations are useful in the treatment of B cell malignancies, such as, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

In vitro and in vivo models are considered indicative of how a certain compound or combination of compounds would behave in humans. In addition, when compounds are combined either in vitro or in vivo, one expects that the combination has only additive effects. Surprisingly, the inventors found that the combination of a particular antibody specific for CD19 and bendamustine mediated a synergistic level of specific cell killing in a chronic B-cell leukemia cell line (MEC-1) in comparison to the antibody and bendamustine alone. This *in vitro* model is indicative of how the combination will work in the treatment of chronic lymphoid leukemia (CLL) in humans. In addition, and also unexpectedly, the inventors found that the combination of a particular antibody specific for CD19 and bendamustine inhibited tumor growth and synergistically increased median survival days and median increase in lifespan, both in Burkitt's lymphoma SCID mouse models, in comparison to the antibody and bendamustine alone. These *in vivo* models are indicative of how the combination will work in the treatment of non-Hodgkin's lymphoma in humans. In summary, the combination of the exemplified anti-CD19 antibody and bendamustine behaved synergistically in models relevant to NHL and CLL. As both NHL and CLL are B cell related disorders and CD19 is highly expressed on B-cells, the exemplified combination would have the same mechanism of action and should also behave synergistically in the treatment of other B cell related disorders, e.g. ALL.

Therefore, the combination of the exemplified antibody specific for CD19 and bendamustine will be effective in the treatment of humans in non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia. In addition, the antibody specific to CD19 exemplified in the present specification has already entered into clinical trials, where such combinations can be confirmed in humans.

As the mechanism of action of bendamustine and other nitrogen mustards are similar, as they are alkylating agents that form interstrand cross-links (ICLs) between DNA bases, thus blocking fundamental processes such as replication and transcription, it is believed that synergy should also be seen when treating humans having non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia with a combination of the exemplified anti-CD19 antibody and a nitrogen mustard other than bendamustine.

As the exemplified anti-CD19 antibody and other anti-CD19 antibodies bind CD19, it is believed that synergy should also be seen when treating humans having non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia with a combination of any anti-CD19 antibody and a nitrogen mustard, e.g., bendamustine.

As the exemplified anti-CD19 antibody binds a specific epitope of CD19, it is believed that antibodies that cross-compete with the exemplified antibody or bind to the same epitope as the exemplified antibody should also behave synergistically when treating humans having non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia when used in combination with a nitrogen mustard, e.g., bendamustine.

An aspect of the present disclosure comprises a synergistic combination wherein the antibody specific for CD19 comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6) and bendamustine. In preferred aspects, the combination is used for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

Description of Drawings

Figure 1 shows the cytotoxicity effects of MOR00208 and bendamustine alone and in combination on MEC-1 cells.

Figure 2 shows the ADCC dose response curves of the combination of MOR00208 and bendamustine in MEC-1 cells.

Figure 3 shows the amino acid sequence of the variable domains of MOR00208.

Figure 4 shows the amino acid sequence of the Fc regions of MOR00208.

Figure 5 shows the normalized specific killing data of Table 2.

Figure 6 shows the results of the human Ramos Burkitt's B-cell lymphoma survival model in SCID mice as described in Example 3. The figure represents the data shown in Table 6, but excludes treatment related deaths.

Figure 7 shows the statistical analysis of the results of the subcutaneously (SC)-implanted human Ramos Burkitt's B-cell lymphoma tumor growth model in SCID mice, as described in Example 2.

Figure 8 shows the results of the subcutaneously (SC)-implanted human Ramos Burkitt's B-cell lymphoma tumor growth model in SCID mice, as described in Example 2.

Figure 9 shows the results of the subcutaneously (SC)-implanted human Ramos Burkitt's B-cell lymphoma tumor growth model in SCID mice, as described in Example 2. In this figure the BEN dosage is 13mg/kg.

Figure 10 shows the results of the subcutaneously (SC)-implanted human Ramos Burkitt's B-cell lymphoma tumor growth model in SCID mice, as described in Example 2. In this figure the BEN dosage is 16mg/kg.

Detailed description of the invention


"Synergy", "synergism" or "synergistic" mean more than the expected additive effect of a combination. The "synergy", "synergism" or "synergistic" effect of a combination is determined herein by the methods of Chou et al., Clarke et al. and/or Webb et al. See Ting-Chao Chou, Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies, *Pharmacol Rev* 58:621–681 (2006), which is incorporated by reference in its entirety. See also Clarke et al., Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents *in vivo* in breast cancer and other models, *Breast Cancer Research and Treatment* 46:255-278 (1997), which is incorporated by reference in its entirety. See also Webb, J. L. (1963) *Enzyme and Metabolic Inhibitors*, Academic Press, New York, which is incorporated by reference in its entirety.

The term "antibody" means monoclonal antibodies, including any isotype, such as, IgG, IgM, IgA, IgD and IgE. An IgG antibody is comprised of two identical heavy chains and two identical light chains that are joined by disulfide bonds. Each heavy and light chain contains a constant region and a variable region. Each variable region contains three segments called "complementarity-determining regions" ("CDRs") or "hypervariable regions", which are primarily responsible for binding an epitope of an antigen. They are referred to as CDR1, CDR2, and CDR3, numbered sequentially from the N-terminus. The more highly conserved portions of the variable regions outside of the CDRs are called the "framework regions". An "antibody fragment" means an Fv, scFv, dsFv, Fab, Fab' F(ab')₂ fragment, or other fragment, which contains at least one variable heavy or variable light chain, each containing CDRs and framework regions.


A "nitrogen mustard" is a nonspecific DNA alkylating agents used as chemotherapy. Alkylating agents add an alkyl group (C_nH_{2n+1}) to nucleic acid bases, e.g., adding an alkyl group to the guanine base of DNA at the number 7 nitrogen atom of the imidazole ring. The alkylation steps result in the formation of interstrand cross-links (ICLs). These ICLs are highly cytotoxic, since they

block fundamental metabolic processes such as replication and transcription. Nitrogen mustards include cyclophosphamide, chlorambucil, uramustine, ifosfamide, melphalan and bendamustine.


Cyclophosphamide is marketed as Endoxan, Cytoxan, Neosar, Procytox, and Revimmune, and is also known as cytophospane. Cyclophosphamide, or combinations including cyclophosphamide, is used in the treatment of lymphomas, leukemia and some solid tumors. Cyclophosphamide has the following structure:




Chlorambucil is marketed as Leukeran by GlaxoSmithKline. It is used mainly in the treatment of chronic lymphocytic leukemia. Chlorambucil has the following structure:




Uramustine is used in the treatment of non-Hodgkin's lymphoma. Uramustine has the following structure:



Ifosfamide is marketed as Mitoxana and Ifex. Ifosfamide has the following structure:




Melphalan is marketed as Alkeran. Melphalan has the following structure:



Bendamustine is marketed under the names Ribomustin®, and Treanda®, and is also known as SDX-105, by Mundipharma International Corporation Limited (Licensee of Astellas Pharma

GmbH) and Cephalon for the treatment of chronic lymphocytic leukemias (CLL), indolent B-cell non-Hodgkin's lymphoma (NHL), and other lymphomas. Bendamustine has the following structure:



"BEN" when used herein means bendamustine.

"VH" refers to the variable region of an immunoglobulin heavy chain of an antibody, or antibody fragment. "VL" refers to the variable region of the immunoglobulin light chain of an antibody, or antibody fragment.

The term "CD19" refers to the protein known as CD19, having the following synonyms: B4, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, CVID3, Differentiation antigen CD19, MGC12802, and T-cell surface antigen Leu-12.

Human CD19 has the amino acid sequence of:

```
MPPRLLFFLLFLTPMEVRPEEPLVVKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKPFLKLSL
GLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEGSGELFRWNVSDLG
GLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLPPRDSL NQSLSQDLTMAPGS
TLWLSCGVPPDSVSRGPLSWTHVHPKGP KSLLSLELKDDRPARDMWV METGLLLPRATAQDAGK
YYCHRG NLTMSFHLEITARPVLWHWLLRTGGWKVSAVTLAYLIFCLCSLVGILHLQRALVLRKRK
RMTDPTRRFFKVTPPPGSGPQNQYGNVLSLPTPTSGLGRAQRWAAGLGGTAPSYGNPSSDVQA
DGALGSRSPPGVGPEEEEEGEGYEEDSEEDSEFYENDSNLGQDQLSQDGSGYENPEDEPLGPE
DEDSFSNAESYENEDEELTQPVARTMDFLSPHGS AWDP SREATSLGSQSYEDMRGILYAAPQLR
SIRGQPGPNHEEDADSYENMDNPDGPDP AWGGGGGRMG TWSTR. (SEQ ID NO: 7)
```

"MOR00208" is an anti-CD19 antibody. The amino acid sequence of the variable domains is provided in Figure 3. The amino acid sequence of the heavy and light chain Fc regions of MOR00208 are provided in Figure 4. "MOR00208" and "XmAb 5574" are used as synonyms to describe the antibody shown in Figures 3 and 4. The MOR00208 antibody is described in US patent application serial number 12/377,251, which is incorporated by reference in its entirety.

Additional antibodies specific for CD19 are described in US patent no. 7,109,304 (Immunomedics), which is incorporated by reference in its entirety; US application serial no. 11/917,750 (Medarex), which is incorporated by reference in its entirety; US application serial no. 11/852,106 (Medimmune), which is incorporated by reference in its entirety; US application serial no. 11/648,505 (Merck Patent GmbH), which is incorporated by reference in its entirety; US patent no. 7,968,687 (Seattle Genetics), which is incorporated by reference in its entirety; and US application serial no. 12/710,442 (Glenmark Pharmaceuticals), which is incorporated by reference in its entirety.

"Fc region" means the constant region of an antibody, which in humans may be of the IgG1, 2, 3, 4 subclass or others. The sequences of human Fc regions are available at IMGT, Human IGH C-REGIONS, http://www.imgt.org/IMGTrepertoire/Proteins/protein/human/IGH/IGHC/Hu_IGHCalleles.html (retrieved on 16 May 2011).

"RefmAb33" is an antibody whose amino acid sequence is as follows:

Heavy chain including the Fc region:

QVTLRESGPALVKPTQTLTLCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKH
YNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTITVTVSSASTKG
PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTV
PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKHTHTCPPCPAPELLGGPDVFLFPPKPKDTLMIS
RTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSFLTIVVHQDWLNGKE
YKCKVSNKALPAAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTTPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
(SEQ ID NO: 8)

Light chain including the Fc region:

DIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRF
SGSGSGTEFTLTISSLQPDFFATYYCFQGSQGYPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT
ASVVCCLNNFYFPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC
EVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 9)

RefmAb33 is specific for RSV, and is used as isotype control, as it shares the same Fc region as MOR00208.

A "combination" means more than one item, e.g. a compound such as an antibody and bendamustine.

The present disclosure also relates to combinations, pharmaceuticals, and pharmaceutical compositions containing the described combinations. The two components of the synergistic combination of the present invention, e.g. the antibody specific for CD19 and bendamustine, may be administered together, simultaneously or separately. When administered together, the two components may be formulated together in one pharmaceutical composition, which may include a pharmaceutical acceptable carrier or excipient. Alternatively the two components might also be formulated in different pharmaceutical compositions. In this case the two components can be administered simultaneously or subsequently. In an embodiment, bendamustine, is administered prior to and/or separately from the administration of the antibody specific for CD19, e.g. MOR00208.

A pharmaceutical composition includes an active agent, eg. an antibody for therapeutic use in humans. A pharmaceutical composition may include acceptable carriers or excipients.

"Administered" or "administration" includes but is not limited to delivery by an injectable form, such as, for example, an intravenous, intramuscular, intradermal or subcutaneous route or mucosal

route, for example, as a nasal spray or aerosol for inhalation or as an ingestible solution, capsule or tablet.

A "therapeutically effective amount" of a compound or combination refers to an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of a given disease or disorder and its complications. The amount that is effective for a particular therapeutic purpose will depend on the severity of the disease or injury as well as on the weight and general state of the subject. It will be understood that determination of an appropriate dosage may be achieved, using routine experimentation, by constructing a matrix of values and testing different points in the matrix, all of which is within the ordinary skills of a trained physician or clinical scientist.

The "CDRs" herein are defined by either Chothia et al or Kabat et al. See Chothia C, Lesk AM. (1987) Canonical structures for the hypervariable regions of immunoglobulins. *J Mol Biol.*, 196(4):901-17, which is incorporated by reference in its entirety. See Kabat E.A, Wu T.T., Perry H.M., Gottesman K.S. and Foeller C. (1991). *Sequences of Proteins of Immunological Interest*. 5th edit., NIH Publication no. 91-3242, US Dept. of Health and Human Services, Washington, DC, which is incorporated by reference in its entirety.

"Cross competes" means the ability of an antibody or other binding agent to interfere with the binding of other antibodies or binding agents to CD19 in a standard competitive binding assay. The ability or extent to which an antibody or other binding agent is able to interfere with the binding of another antibody or binding molecule to CD19, and, therefore whether it can be said to cross-compete according to the invention, can be determined using standard competition binding assays. One suitable assay involves the use of the Biacore technology (e.g. by using the BIAcore 3000 instrument (Biacore, Uppsala, Sweden)), which can measure the extent of interactions using surface plasmon resonance technology. Another assay for measuring cross-competing uses an ELISA-based approach. A high throughput process for "epitope binning" antibodies based upon their cross-competition is described in International Patent Application No. WO 2003/48731

The term "epitope" includes any protein determinant capable of specific binding to an antibody or otherwise interacting with a molecule. Epitopic determinants generally consist of chemically active surface groupings of molecules such as amino acids or carbohydrate or sugar side chains and can have specific three-dimensional structural characteristics, as well as specific charge characteristics. An epitope may be "linear" or "conformational." The term "linear epitope" refers to an epitope with all of the points of interaction between the protein and the interacting molecule (such as an antibody) occur linearly along the primary amino acid sequence of the protein (continuous). The term "conformational epitope" refers to an epitope in which discontinuous amino acids that come together in three dimensional conformation. In a conformational epitope, the points of interaction occur across amino acid residues on the protein that are separated from one another.

"Binds the same epitope as" means the ability of an antibody or other binding agent to bind to CD19 and having the same epitope as the exemplified antibody. The epitopes of the exemplified antibody and other antibodies to CD19 can be determined using standard epitope mapping techniques. Epitope mapping techniques, well known in the art, include Epitope Mapping Protocols in *Methods in Molecular Biology*, Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, New Jersey. For example, linear epitopes may be determined by e.g., concurrently synthesizing large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies while the peptides are still attached to the supports. Such techniques are known in the art and described in, e.g., U.S. Patent No. 4,708,871 ; Geysen et al, (1984) *Proc. Natl. Acad. Sci. USA* 8:3998-4002; Geysen et al, (1985) *Proc. Natl. Acad. Sci. USA* 82:78-182; Geysen et al, (1986) *Mol. Immunol.* 23 :709-715. Similarly, conformational epitopes are readily identified by determining spatial conformation of amino acids such as by, e.g., hydrogen/deuterium exchange, x-ray crystallography and two-dimensional nuclear magnetic resonance. See, e.g., *Epitope Mapping Protocols*, supra. Antigenic regions of proteins can also be identified using standard antigenicity and hydropathy plots, such as those calculated using, e.g., the Omega version 1.0 software program available from the Oxford Molecular Group. This computer program employs the Hopp/Woods method, Hopp et al, (1981) *Proc. Natl. Acad. Sci. USA* 78:3824-3828; for determining antigenicity profiles, and the Kyte-Doolittle technique, Kyte et al, (1982) *J. Mol. Biol.* 157: 105-132; for hydropathy plots.

Embodiments

An aspect of the present disclosure comprises a combination of an antibody specific for CD19 and a nitrogen mustard for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia. In embodiments, the combination is synergistic.

Herein, the combination of the exemplified anti-CD19 antibody and bendamustine behaved synergistically in *in vitro* and *in vivo* models relevant to NHL and CLL. As both NHL and CLL are B cell related disorders and CD19 is highly expressed on B-cells, the exemplified combination should have the same mechanism of action and should also behave synergistically in the treatment of other B cell related disorders, e.g. ALL. Therefore, the combination of the exemplified antibody specific for CD19 and bendamustine will be effective in the treatment of humans in non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

As the mechanism of action of bendamustine and other nitrogen mustards are similar, as they are alkylating agents that form interstrand cross-links (ICLs) between DNA bases, thus blocking fundamental processes such as replication and transcription, it is believed that synergy should also be seen when treating humans having non-Hodgkin's lymphoma, chronic lymphocytic leukemia

and/or acute lymphoblastic leukemia with a combination of the exemplified anti-CD19 antibody and a nitrogen mustard other than bendamustine, e.g. cyclophosphamide, chlorambucil, uramustine, ifosfamide, and melphalan.

As the exemplified anti-CD19 antibody and other anti-CD19 antibodies bind CD19, it is believed that synergy should also be seen when treating humans having non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia with a combination of any anti-CD19 antibody and a nitrogen mustard, where the anti-CD19 antibody is, for example, described in US patent application serial number 12/377,251 (Xencor), WO2005012493, WO2010053716 (Immunomedics); WO2007002223 (Medarex); WO2008022152 (Xencor); WO2008031056 (Medimmune); WO 2007/076950 (Merck Patent GmbH); WO 2009/052431 (Seattle Genetics); and WO2010095031 (Glenmark Pharmaceuticals), all of which are incorporated by reference in their entireties.

In embodiments, the antibody specific for CD19 comprises an antibody that cross-competes with the antibody comprising an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).

In embodiments, the antibody specific for CD19 comprises an antibody that binds to the same epitope as an antibody comprising an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).

In embodiments, the antibody specific for CD19 comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).

In embodiments, the antibody specific for CD19 comprises a variable heavy chain of the sequence EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTTYNEKFQGRVTISDDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGGQTLVTVSS (SEQ ID NO: 10) and a variable light chain of the sequence DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYR

MSNLNSGVPDRFSGSGSGTEFTLTISSELEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 11).

In embodiments, the antibody specific for CD19 comprises a heavy chain constant domain of the sequence

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVH
TFPAVLQSSGLYSLSSWTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL
GGPDVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTF
RVVSVLTVVHQDWLNGKEYKCKVSNKALPAAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSL
TCLVKGFYPSDIAVEWESNGQPENNYKTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMH
EALHNHYTQKSLSLSPGK. (SEQ ID NO: 12)

In embodiments, the antibody specific for CD19 comprises a light chain constant domain of the sequence

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
STYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC. (SEQ ID NO: 13)

In embodiments, the nitrogen mustard is bendamustine.

In embodiments, the components of the combination, the antibody specific for CD19 and bendamustine, are administered separately. In an embodiment, bendamustine is administered prior to administration of the antibody specific for CD19.

In embodiments the combination is a pharmaceutical composition. In embodiments, the composition comprises an acceptable carrier. In embodiments, the combination is administered in an effective amount.

In another aspect the synergistic combination of an antibody specific for CD19 comprising an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6) and bendamustine is able to mediate killing of MEC-1 cells by ADCC in the presence of isolated human PBMCs with an at least two-fold, three-fold, four-fold, or five-fold better efficacy than bendamustine alone.

An aspect of the present disclosure comprises a synergistic combination of an antibody specific for CD19 comprising an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6) and bendamustine for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia. In embodiments, the non-Hodgkin's

lymphoma is selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid tissue, marginal zone, diffuse large B cell, Burkitt's, and mantle cell.

Another aspect comprises a method of treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia in an individual in need thereof, which method comprises administration of an antibody specific for CD19 and a nitrogen mustard. In embodiments of the method, the antibody specific for CD19 comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6). In embodiments of the method, the antibody comprises the exemplified antibody specific for CD19. In embodiments of the method the nitrogen mustard is bendamustine.

Examples

Example 1: Inhibition of proliferation of MEC-1 cells using MOR00208 and bendamustine alone and in combination

Materials

MEC-1 cells: chronic B-cell leukemia cell line DSMZ# ACC497; Cell Medium: Iscove's Modified Dulbecco's Medium (IMDM) with GlutaMAX™, Invitrogen, Cat No.: 31980-048, 20% FCS; PBMCs: RPMI1640, with stabile Glutamine, PAN Biotech GmbH, Cat No.: P04-13500 supplemented with 10% FCS; Biocoll: Biochrome AG CAT No.: L6115 LOT No.: 1050T; Bendamustine: Mundipharma LOT No.: 88018; FCS: PAN CAT No.: 3302-P282403 LOT No.: P282403; and RefmAb33 (anti-RSV) with same Fc region as MOR00208.

Methods

The cytotoxicity of MOR00208 and bendamustine alone and in combination was tested in MEC-1 cells. BEN is an alkylating agent, therefore, functions via direct cytotoxicity in MEC-1 cells. MOR00208 targets CD19 and additionally functions via ADCC in killing MEC-1 cells. For the following groups MEC-1 cell killing was measured: BEN at 100µg/ml; MOR00208 at 6,6pm and the combination of MOR00208 at 6,6pm and BEN at 100µg/ml. These concentrations were chosen as they are near or at the EC50 for MOR00208 and BEN. The following were used as controls: RefmAb33, or PBMCs alone. In both the BEN group and MOR00208+BEN combination group, MEC-1 cells were pre-incubated with BEN 48 hours prior to the ADCC assay measurements. The MEC-1 cells were stained using 1mg/ml Calcein AM then counted and adjusted to 2×10^5 /ml. The

PBMCs were counted and adjusted to $6 \times 10^6/\text{ml}$. The cell killing assays were done as follows: using 96 well plates, a 100 μl cell suspension of MEC-1 cells was added per well, then 100 μl cell suspension of PBMCs was added to each well resulting in an E:T ratio of 30:1. The antibodies were diluted to 1 $\mu\text{g}/\text{ml}$ in medium. Cells were centrifuged and re-suspended. To the target:effector cell-pellet, 100 μl antibody solution or according control solution was added. The mixture was incubated for 4h in CO₂-incubator at 37°C. The cell killing measurements were taken as follows: the incubated cell solution (~100 μl) was transferred into FACS tubes and 200 μl FACS buffer (DPBS + 3%FCS) and 0,5 μl PI stock solution was added to each tube. FACS-Calibur was used. Dead MEC-1 cells were stained with propidium iodide. Table 1 and Figure 1 show the raw data.

Table 1

	Control	MOR00208 6,6pm	BEN 100 $\mu\text{g}/\text{ml}$	BEN+MOR00208 combination
Experiment 1	25,2	73,6	83,6	94,0
Experiment 2	18	41,5	53,3	64,9
Experiment 3	30,9	57,2	75,6	83,6

The values represent % dead cells. Each experiment represents PBMCs from different donors. The controls used for each experiment was RefMab33.

Table 2 shows the raw data of Table 1 normalized for specific killing and the results of the Chou calculations done in the determination of synergism.

Table 2

	Bendamustine 100 $\mu\text{g}/\text{ml}$	MOR00208 6.6 pM	Ben + MOR00208 (combination)	Chou Index
Experiment 1	0.85	0.70	1.0	0.2
Experiment 2	0.75	0.50	1.0	0.7
Experiment 3	0.85	0.50	1.0	0.8
Average	0.8	0.6	1.0	0.6

The values shown in Table 2 are calculated as follows: 1) from the raw data (% dead cells) shown in Table 1, the background (controls) were subtracted, resulting in the specific killing for each treatment group; then 2) the specific killing values were normalized by setting the combination of MOR00208 + BEN to 1. The averages of Table 2 are depicted in Figure 5. Example ADCC dose response curves used in the Chou factor calculations of the MOR00208 + BEN combination are

shown in Figure 2.

Chou Index (CI) calculations were completed in order to determine synergy of the combination of the exemplified anti-CD19 antibody and bendamustine as compared to MOR00208 and BEN alone. Such calculations are described in Ting-Chao Chou, Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies, Pharmacol Rev 58:621–681 (2006), which is incorporated by reference in its entirety and Chou TC, Talalay P, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55 (1984), which is incorporated by reference in its entirety. The methods of Chou-Talalay are carried out using the CI-isobol method.

Median-effect equation

The median-effect equation models the effect of an inhibitor (such as a drug) as $F_a/F_u = (D/D_{50})^m$, where D is the dose, F_a and F_u is the fraction of the system affected and unaffected by the dose D ($F_a + F_u = 1$); D_{50} is the dose producing the median effect (e.g. IC₅₀, ED₅₀, LD₅₀). The constant m determines the shape of the dose-effect curve.

We used Excel Fit software to carry out a linear regression calculation to estimate the parameters m and D_{50} .

The effects of the combination on MEC-1 cells is measured % cell death as described above. We define the fraction F_u to be the ratio of % cell death of the treated cell line to the % cell death of the cell line exposed to a control. That is:

$$F_u = \% \text{ cell death (treated cell line)} / \% \text{ cell death (non-treated cell line)}$$

Then the % cell death of a cell line is the constant D_{50} in the median effect equation, which can be estimated by the linear regression described above.

CI-isobol method

The CI-isobol method provides a quantitative assessment of synergism between drugs. A combination index (CI) is estimated from dose-effect data of single and combined drug treatments. A value of CI less than 1 indicates synergism; CI = 1 indicates additive effect; and CI > 1 indicates antagonism. Drug interaction (synergism or antagonism) is more pronounced the farther a CI value is from 1.

Formally, the combination index (CI) of a combined drug treatment is defined as

$$CI = D_1/D_{x1} + D_2/D_{x2}$$

Here D_1 and D_2 are the doses of drug 1 and drug 2 of the combination, respectively; and D_{x1} , and D_{x2} is the dose of a treatment with only drug 1 and drug 2 that would give the same effect as that

of the combination. The doses Dx1 and Dx2 need to be estimated from the dose-effect data of single drug treatments. Essentially, a median effect equation is fitted to the data of each drug. From the median effect equation of a drug, we can estimate the dose (i.e. D) necessary to produce an effect (i.e. Fa, Fu). The further a point lies from the additive line, the bigger the different between 1 and its CI, thus the stronger the (synergistic or antagonistic) effect is.

Results

As shown in Table 2, the Chou index values indicate clear synergism of the combination of MOR00208 and bendamustine in the specific killing of MEC-1 cells as compared to MOR00208 and bendamustine alone. This conclusion is based upon the Chou calculations of 0,2, 0.7 and 0.75 of each of the three experiments, respectively, having an average of 0,6, where a CI <1 indicates synergism. Therefore, the combination of MOR00208 and bendamustine will also behave synergistically in the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphoid leukemia (CLL), and acute lymphoblastic leukemia (ALL) in humans. In order to confirm the results of the above Chou calculations, the normalized data of Table 2 was evaluated for statistical significance using the Bonferroni's Multiple Comparison Test. See James, et al, Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice, Blood, 114(27):5454-63 (Epub 2009 Oct 30), which is incorporated by reference in its entirety. The results are shown in Table 3.

Table 3

Bonferroni's Multiple Comparison Test	Mean Diff.	T value	Significant? (P < 0.05)	Summary
Bendamustine (100µg/ml) vs. BEN + MOR 208 combination	-0.1834	2.997	Yes	*
MOR00208 (6.6pM) vs. BEN + MOR00208 combination	-0.4321	7.060	Yes	***

** p < 0,05

*** p < 0,001

Results

As shown in Table 3, the Bonferroni's Multiple Comparison Test shows that the combination treatment of BEN + MOR00208 is statistically more effective in the specific killing of MEC-1 cells than the treatment of BEN and MOR00208 alone.

Example 2: MOR00208 and BEN alone and in combination in subcutaneously (SC)-implanted human Ramos Burkitt's B-cell lymphoma tumor growth model.

Materials

RAMOS human Burkitt's lymphoma cells (ATCC number CRL-1596, lot# 3953138); Vehicle control: 150 mM NaCl, 25 mg/mL mannitol, pH 5.5-6.0; (adjusted with 0.01 M NaOH).

Ref_mAb_33_IgG_Xen (10 mg/mL in PBS, referred to as Ref_mAb_33). Six-week-old, female, C.B-17 SCID mice (CB17/lcr-Prkdcscid/lcrIcoCrI) were purchased from Charles River Laboratories (Wilmington, MA) and acclimated in the laboratories for nine days prior to experimentation.

Methods

SCID mice were implanted sub-cutaneously with RAMOS cells ($\sim 5 \times 10^6$ cells/mouse). When the mice had tumors of approximately 150 mm³ in size, or ~14 days after inoculation, they were separated into groups, where each group had tumor volumes of relatively the same size. Treatments began on Day 15. The treatment regimens are provided in Table 4. The study duration was 60 days.

Table 4

Group No.	No. of Animals	Test Articles	Dose (mg/kg)	Treatment Route and Schedule
A/B	10	Bendamustine	13, and 16	IP, Q1Dx5
D	10	MOR00208	6/10	IV, 6 mg/kg Q3Dx2; 10mg/kg Q3Dx2/3 wks starting on Day 22
E	10	Vehicle/ Ref_mAb_33	6/10	IP, Q1Dx5 IV, 6 mg/kg Q3Dx2 ; 10 mg/kg Q3Dx2/3 wks starting on day 22
F/G	10	MOR00208/ Bendamustine	6 or 10/13 and 6 or 10/16	MOR00208 and BEN as above

Due to a technician error MOR00208 on Day 18 was not administered.

MOR00208, and bendamustine, were administered in a volume of 0.1 mL/10 g of body weight. MOR00208 and vehicle control/Ref_mAb_33 at a concentration of 0.6/1.0 mg/mL, and bendamustine at concentration of 1.3, and 1.6 mg/mL.

The readouts were 1) Median days to reach 4000 mg in size, where the statistical analysis was done using the log rank test and 2) Tumor size on study day 34, where the statistical analysis was done using the One-Way-ANOVA and Bonferroni's post hoc tests. (Raw data not shown). Tumor weights were calculated using the equation $(l \times w^2)/2$, where l and w refer to the larger and smaller dimensions collected at each measurement. The results are shown in Figures 7-10. The combination therapy was not significantly superior to the respective monotherapies in this subcut model, as compared to the clear synergy shown in the orthotopic survival model below. This is considered to be related to the ineffective MOR00208 dosing regimen in this model. The orthotopic survival model described below, however, is believed to be more predictive of how well the combination treatment would work in the treatment of CLL, NHL, and ALL in humans, as the orthotopic model better mimics the multifocal disease nature, including an involvement of the vascular system, as compared to the subcut, solid tumor model above.

Example 3 MOR00208 and bendamustine alone and in combination in human Non-hodgkin RAMOS tumor in SCID mice, survival model

Materials

Cyclophosphamide (Baxter, Lot. No.1A548C); Vehicle Control: 0.9% sodium chloride, 25mg/ml mannitol, pH 6.5-6.8 (adjusted with 0.01 M NaOH); SCID Mice (University of Adelaide, Waite Campus, Urrbarraie, SA, Australia, Strain C.B.-17-Igh-1^b-Prkdc^{scid}); RAMOS human Burkitt's lymphoma cells (ATCC number CRL-1596); Ref_mAb_33_IgG_Xen (10 mg/mL in PBS, referred to as Ref_mAb_33); Bendamustine (Mundipharma, Lot No. 83889).

Methods

SCID mice were pre-treated with Cyclophosphamide (75 mg/kg, i.p., twice daily) for two days prior to RAMOS cell inoculation (Day -2 and -1). On the day of inoculation (Day 0), the mice were separated into seven groups of ten mice each, and inoculated with 1×10^6 RAMOS cells each intravenously into the tail vein. The planned dosing regimen for each group is shown in Table 5 and commenced on Day 3. The study duration was 60 days.

Table 5: Dosing regimen

Group	Compound	Treatment	Schedule
2 and 3	Bendamustine	13/16 mg/kg, i.p, in 10 mL/kg	Once daily (Days 5-9)
1	MOR00208	3 mg/kg, i.v., in 10 mL/kg	Twice weekly for 3 weeks (Days 3, 6, 10, 13, 17 and 20)
10	Vehicle Control	i.p., 10 mL/kg	Once daily (Days 5-9)
5 and 6	Bendamustine /MOR00208	13/16 mg/kg, i.p; 3 mg/kg, i.v. in 10 mL/kg;	Once daily (Days 5-9) /twice weekly for 3 weeks(Days 3, 6, 10, 13, 17 and 20)
4	Bendamustine	26 mg/kg, i.p, in 10 mL/kg	Once daily (Days 5-9)
10	Ref mAb	3 mg/kg, i.v.	Day 3, 6, 10, 13, 17 and 20

The survival data is shown in Table 6 and Figure 6.

Table 6: Death of mice

Group	Compound	Treatment	Death of Mice over the Course of Study [Day post Inoculation]
1	MOR00208	3 mg/kg, i.v.	25; 29; 29; 30; 31; 33; 35; 38; 38; 39
2	Bendamustine	13 mg/kg, i.p.	10*; 21; 21; 23; 24; 24; 24; 24; 25; 26
3	Bendamustine	16 mg/kg, i.p.	24; 24; 24; 24; 24; 24; 25; 26; 26; 27
4	Bendamustine	26 mg/kg, i.p.	10*; 10*; 10*; 10*; 10*; 12*; 12*; 14*; 16*; 23
5	Bendamustine/ MOR00208	13/3 mg/kg, i.p. / i.v.	12*; 30; 33; 33; 35; 40; 45; 45; 56; 56
6	Bendamustine/ MOR00208	16/3 mg/kg, i.p. / i.v.	33; 35; 38; 39; 40; 40; 45; 45; 45; 45
10	Vehicle/ Ref_mAb	i.p. / 3 mg/kg, i.v.	24; 24; 25; 25; 25; 26; 26; 26; 26; 29

* Compound toxicity related death

From the raw data shown in Table 6, both the median survival in days and median increase in lifespan were calculated. All treatment related deaths were excluded in the calculations. The results are shown in Table 7.

Table 7

Group	Treatment	Median Survival (Days Post-Inoculation)	Median % Increase in Lifespan (ILS) [§]	Evaluation of combinatorial effects
1	MOR00208	32 ^a	25.5	n.a.
2	Bendamustine 13 mg/kg	24 ^b	-5.88	n.a.
3	Bendamustine 16 mg/kg	24 ^c	-5.88	n.a.
4	Bendamustine 26 mg/kg	n.a.	n.a.	n.a.
5	Bendamustine/ MOR00208 13/3 mg/kg	40 ^d	56.86	Synergy/Potentiation*
6	Bendamustine/ MOR00208 16/3 mg/kg	40 ^d	56.86	Synergy/Potentiation**
10	Vehicle/ Ref_mAb 3 mg/kg	25.5	n.a.	n.a.

a significantly different to Vehicle control/ Ref_mAb_33 (Group 10) ($p < 0.001$), Bendamustine at 13 mg/kg (Group 2) ($p < 0.001$), Bendamustine/ MOR00208 at 13/3 mg/kg (Group 5) ($p < 0.05$) and Bendamustine/ MOR00208 at 16/3 mg/kg (Group 6) ($p < 0.001$).

b significantly different to Vehicle control/ Ref_mAb_33 (Group 10) ($p < 0.05$) and Bendamustine/ MOR00208 at 13/3 mg/kg (Group 5) ($p < 0.001$).

c significantly different to Bendamustine/ MOR00208 at 16/3 mg/kg (Group 6) ($p < 0.001$).

d significantly different to Vehicle Control/ Ref_mAb_33 (Group 10) ($p < 0.001$).

§ vs. vehicle control/ Ref_mAb_33

* Synergy/Potentiation vs. the respective monotherapy groups as ILSCombo (56.86%) > ILSMOR00208 3mg/kg + ILSBendamustine 13mg/kg (25.5% + (-5.88)% = 19.62%)

** Synergy/Potential vs. the respective monotherapy groups as ILSCombo (56.86%) > ILSMOR00208 3mg/kg + ILSBendamustine 16mg/kg (25.5% + (-5.88)% = 19.62%).

Median % Increased Lifespan (ILS) is calculated as follows:

Mean % Increase in Lifespan = $(\text{Survival}_{\text{Treatment}} - \text{Mean Survival}_{\text{Control}}) / \text{Mean Survival}_{\text{Control}} * 100$.

Survival times are measured in days post-inoculation.

Classification of Combinatorial Effects

The classification of the MOR00208/Bendamustine combination therapy (combo) effect was evaluated by comparing the ILS of the combination with the added ILS of the respective monotherapies:

Synergy/Potential*: ILSCombo > ILSMOR00208 3mg/kg + ILSBendamustine. Synergistic effects are classified as potentiation if at least one of the monotherapies has no effect. Additivity: ILSCombo = ILSMOR00208 3mg/kg + ILSBendamustine. Antagonism: ILSCombo < ILSMOR00208 3mg/kg + ILSBendamustine.

In addition to an analysis of the data for purposes of identifying synergy, the following statistical analysis was also completed. Statistical analyses were carried out using the median values. Any animal that died unexpectedly or was culled prior to Day 17 of the study in the Test Article treatment groups was excluded from survival analysis calculation. The death/ culling of these animals was attributed to compound toxicity rather than disease progression as they occurred well in advance of the first deaths in the Vehicle Control animals. A survival curve was created using the product limit of Kaplan and Meier, and survival curves compared using the log-rank (Mantel-Cox) test. Where significant differences were found, All Pairwise Multiple Comparison (Holm-Sidak Test) was performed. Comparison was done between all groups. In addition the comparison of the following groups were summarised in separate figures for each test article: Vehicle Control/ Ref_mAb (group 10) against Bendamustine groups (Groups 2, 3 and 4) and Vehicle Control / Ref_mAb (group 10) against Combination groups (Groups 5 and 6) or respective MOR00208 monotherapy group (group 1). A p value of less than 0.05 was considered significant. Results are shown in Tables 8-10.

Table 8:**Vehicle Control, MOR00208 and Bendamustine Monotherapy:**Log-rank (Mantel-Cox) Test: There is a significant difference ($p < 0.001$).

All Pairwise Multiple Comparison Procedure (Holm-Sidak method):

Group	Treatment	Group 1	Group 2	Group 3
10	Vehicle Control/ Ref_mAb (3 mg/kg)	***Yes	*Yes	No
1	MOR00208 (3 mg/kg)		***Yes	***Yes
2	Bendamustine (13 mg/kg)			No
3	Bendamustine (16 mg/kg)			

***Yes: There is a statistically significant difference ($p < 0.001$).*Yes: There is a statistically significant difference ($p < 0.05$).No: There is no statistically significant difference ($p \geq 0.05$).Table 9:**Vehicle Control, MOR00208/ Bendamustine Combination –Therapy and respective Monotherapy:**Log-rank (Mantel-Cox) Test: There is a significant difference ($p < 0.001$).

All Pairwise Multiple Comparison Procedure (Holm-Sidak method):

Group	Treatment	Group 1	Group 5	Group 2
10	Vehicle Control/ Ref_mAb (3 mg/kg)	***Yes	***Yes	*Yes
1	MOR00208 (3 mg/kg)		*Yes	***Yes
5	MOR00208/ Bendamustine (3/13 mg/kg)			***Yes
2	Bendamustine (13 mg/kg)			

***Yes: There is a statistically significant difference ($p < 0.001$).*Yes: There is a statistically significant difference ($p < 0.05$).

Table 10:**Vehicle Control, MOR00208/ Bendamustine Combination –Therapy and respective Monotherapy:**Log-rank (Mantel-Cox) Test: There is a significant difference ($p < 0.001$).

All Pairwise Multiple Comparison Procedure (Holm-Sidak method):

Group	Treatment	Group 1	Group 6	Group 3
10	Vehicle Control/ Ref_mAb (3 mg/kg)	***Yes	***Yes	No
1	MOR00208 (3 mg/kg)		***Yes	***Yes
6	MOR00208/ Bendamustine (3/16 mg/kg)			***Yes
3	Bendamustine (16 mg/kg)			

***Yes: There is a statistically significant difference ($p < 0.001$).No: There is no statistically significant difference ($p \geq 0.05$).Results

As shown in Tables 7-10 and Figure 6, the combination of MOR00208 and bendamustine behaved synergistically and was statistically significant in the Non-hodgkin RAMOS orthotopic tumor survival model as compared to MOR00208 and bendamustine alone.

It is to be understood that the description, specific examples and data, while indicating exemplary embodiments, are given by way of illustration and are not intended to limit the present invention. Various changes and modifications within the present invention will become apparent to the skilled artisan from the discussion, disclosure and data contained herein, and thus are considered part of the invention.

We Claim:

1. A synergistic combination of an antibody specific for CD19 comprising an antibody that cross-competes with an antibody comprising an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6) and bendamustine for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
2. A combination according to claim 1, wherein the antibody comprises an antibody that binds to the same epitope as an antibody comprising an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).
3. A combination according to claim 1 or 2, wherein the antibody comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).
4. A combination according to any one of the preceding claims, wherein the antibody comprises a variable heavy chain of the sequence
EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPY
NDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDAMYYCARGTYYYGTRVFDYWG
QGTLTVVSS (SEQ ID NO: 10) and a variable light chain of the sequence
DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYR
MSNLNSGVPDRFSGSGSGTEFTLTISLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 11).
5. A combination according to any one of the preceding claims, wherein the antibody comprises a heavy chain constant domain of the sequence

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVH
TFPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL
GGPDVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTF
RVVSVLTVVHQDWLNGKEYKCKVSNKALPAAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSL
TCLVKGFYPSDIAVEWESNGQPENNYKTTPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
EALHNHYTQKSLSLSPGK (SEQ ID NO: 12).

6. A combination according to any one of the preceding claims, wherein said antibody specific for CD19 and bendamustine are administered separately.
7. A combination according to any one of the preceding claims, wherein bendamustine is administered prior to administration of the antibody specific for CD19.
8. A combination according to any one of the preceding claims, which is able to mediate killing of MEC-1 cells by ADCC in the presence of isolated human PBMCs with an at least two-fold better efficacy than bendamustine alone.
9. A combination according to any one of the preceding claims for use in the treatment of non-Hodgkin's lymphoma, wherein the non-Hodgkin's lymphoma is selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid tissue, marginal zone, diffuse large B cell, Burkitt's, and mantle cell.

Figure 1
Cytotoxicity of MOR00208 and BEN alone and in combination




Figure 2

ADCC Dose response curves




Figure 3

The amino acid sequence of the MOR00208 Variable Heavy Domain is:
(The CDRs are bolded and underlined)

EVQLVESGGGLVKPGGSLKLSCAASGYTFT**SYVMHWVRQAPGKGLEWIGYINPY**
NDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYICAR**GTYYYGTRVFDYWG**
QGTLLTVSS (SEQ ID NO: 10)

The amino acid sequence of the MOR00208 Variable Light Domain is:
(The CDRs are bolded and underlined)

DIVMTQSPATLSLSPGERATLSC**RSSKSLQNVNGNTYLY**WFQQKPGQSPQLLIY**R**
MSNLNSGVDPDRFSGSGSGTEFTLTISSELPEDFAVYYC**MQHLEYPIT**FGAGTKLEIK (SEQ
ID NO: 11)

The amino acid sequence of the MOR00208 HCDR1 is: SYVMH (SEQ ID NO: 1)

The amino acid sequence of the MOR00208 HCDR2 is: NPYNDG (SEQ ID NO: 2)

The amino acid sequence of the MOR00208 HCDR3 is: GTYYYGTRVFDY (SEQ ID
NO: 3)

The amino acid sequence of the MOR00208 LCDR1 is: RSSKSLQNVNGNTYLY
(SEQ ID NO: 4)

The amino acid sequence of the MOR00208 LCDR2 is: RMSNLNS (SEQ ID NO: 5)

The amino acid sequence of the MOR00208 LCDR3 is: MQHLEYPIT (SEQ ID NO: 6)

Figure 4

Sequence of Fc regions

The amino acids sequence of the MOR00208 heavy chain Fc region is:


ASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVH
TFPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC
PAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVQFNWYVDGVEVHNAKT
KPREEQFNSTFRVSVSLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQV
YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPMLDSDGSFFLYS
KLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 12)

The amino acids sequence of the MOR00208 light chain Fc region is:

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
DSKD STYLSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 13)

Figure 5

Normalized specific killing; SD; MEC-1 target cells pretreated with Bendamustine (Ben) for 48 h before ADCC; pool of 3 independent experiments with 3 different effector cell donors



The figure shows the averages from the data shown in Table 2.

Figure 6




Figure 7

	Log rank test [Comparison of Kaplan Meyer curves]	One-Way-ANOVA + Bonferroni Multiple Comparison Test
vehicle control vs MOR00208 [6 or 10 mg/kg]	ns	ns
vehicle control vs Bendamustine [13 mg/kg]	ns	ns
vehicle control vs Bendamustine [16 mg/kg]	ns	ns
vehicle control vs MOR00208/Bendamustine [10/13 mg/kg]	ns	ns
vehicle control vs MOR00208/Bendamustine [6 or 10/16 mg/kg]	* p = 0.048	ns
MOR00208 10 mg/kg vs MOR208/Bendamustine [6 or 10/16 mg/kg]	ns	ns
MOR00208 10 mg/kg vs MOR208/Bendamustine [6 or 10/13 mg/kg]	ns	ns
Bendamustine 16 mg/kg vs MOR208/Bendamustine [6 or 10/16 mg/kg]	ns	ns
Bendamustine 13 mg/kg vs MOR208/Bendamustine [6 or 10/13 mg/kg]	* p = 0.0266	ns

Figure 8

	Median days to 4000 mg	Increased time to 4000 mg [%]	Mean Tumor size at study day 34 [mg]	Reduced tumor size at study day 34 [%]
Vehicle control/Ref_mAb_33	38.1	0.00	2683	0.0
MOR00208 [6 or 10 mg/kg]	39.7	4.20	2375	11.5
Bendamustine [13 mg/kg]	38.3	0.52	2593	3.4
Bendamustine [16 mg/kg]	40.8	7.09	1948	27.4
MOR208/Bendamustine [6 or 10/13 mg/kg]	42.2	10.76	2261	15.7
MOR208/Bendamustine [6 or 10/16 mg/kg]	42.5	11.55	1771	34.0

Figure 9





Figure 10



INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2012/065906

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K39/395 C07K16/28
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, EMBASE, FSTA, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2007/154473 A1 (SUPER MICHAEL [US] ET AL) 5 July 2007 (2007-07-05) cited in the application paragraph [0151]	1-9
X	WO 2007/076950 A1 (MERCK PATENT GMBH [DE]; SUPER MICHAEL [US]; DAVIS JONATHAN H [US]; STE) 12 July 2007 (2007-07-12) cited in the application page 41	1-9
	----- -/--	



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

24 October 2012

Date of mailing of the international search report

30/11/2012

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Sirim, Pinar

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2012/065906

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KALOS MICHAEL ET AL: "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", SCIENCE TRANSLATIONAL MEDICINE, vol. 3, no. 95, 10 August 2011 (2011-08-10), XP002667262, cited in the application the whole document	1-9
A	----- WO 2006/065392 A2 (CEPHALON INC [US]; BENDALL HEATHER HELENE [US]; ELLIOTT GARY T [US]; L) 22 June 2006 (2006-06-22) cited in the application the whole document	1-9
A	----- BREMER KARL: "High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, vol. 128, no. 11, 1 November 2002 (2002-11-01), pages 603-609, XP002551065, ISSN: 0171-5216, DOI: 10.1007/S00432-002-0378-6 [retrieved on 2002-10-26] cited in the application the whole document	1-9
A	----- SCHEUERMANN R H ET AL: "CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy", LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, vol. 18, no. 5-6, 1 August 1995 (1995-08-01), pages 385-397, XP009155469, ISSN: 1042-8194 cited in the application the whole document	1-9
X	----- SADELAIN MICHEL ET AL: "The promise and potential pitfalls of chimeric antigen receptors", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 21, no. 2, 2 April 2009 (2009-04-02), pages 215-223, XP002667114, ISSN: 0952-7915 cited in the application the whole document ----- -/--	1-9

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2012/065906

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2008/150494 A1 (XENCOR INC [US]; CHU SEUNG YUP [US]; DESJARLAIS JOHN R [US]; KARKI SHE) 11 December 2008 (2008-12-11) cited in the application page 77 -----	1-9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2012/065906

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2007154473	A1	05-07-2007	AT 509954 T 15-06-2011
		AU 2006332155 A1 12-07-2007	
		BR PI0620795 A2 22-11-2011	
		CA 2635623 A1 12-07-2007	
		CN 101351477 A 21-01-2009	
		DK 1966245 T3 18-07-2011	
		EA 200870132 A1 30-12-2008	
		EP 1966245 A1 10-09-2008	
		EP 2270050 A1 05-01-2011	
		ES 2365046 T3 21-09-2011	
		JP 2009521912 A 11-06-2009	
		KR 20080090485 A 08-10-2008	
		PT 1966245 E 31-08-2011	
		US 2007154473 A1 05-07-2007	
		WO 2007076950 A1 12-07-2007	
		ZA 200806609 A 25-11-2009	
WO 2007076950	A1	12-07-2007	AT 509954 T 15-06-2011
		AU 2006332155 A1 12-07-2007	
		BR PI0620795 A2 22-11-2011	
		CA 2635623 A1 12-07-2007	
		CN 101351477 A 21-01-2009	
		DK 1966245 T3 18-07-2011	
		EA 200870132 A1 30-12-2008	
		EP 1966245 A1 10-09-2008	
		EP 2270050 A1 05-01-2011	
		ES 2365046 T3 21-09-2011	
		JP 2009521912 A 11-06-2009	
		KR 20080090485 A 08-10-2008	
		PT 1966245 E 31-08-2011	
		US 2007154473 A1 05-07-2007	
		WO 2007076950 A1 12-07-2007	
		ZA 200806609 A 25-11-2009	
WO 2006065392	A2	22-06-2006	AR 054094 A1 06-06-2007
		AU 2005317047 A1 22-06-2006	
		CA 2585659 A1 22-06-2006	
		CN 101933923 A 05-01-2011	
		EP 1814544 A2 08-08-2007	
		JP 2008519047 A 05-06-2008	
		US 2006128777 A1 15-06-2006	
		US 2009209606 A1 20-08-2009	
		WO 2006065392 A2 22-06-2006	
WO 2008150494	A1	11-12-2008	AU 2008260498 A1 11-12-2008
		CA 2693053 A1 11-12-2008	
		EP 2176298 A1 21-04-2010	
		US 2009136485 A1 28-05-2009	
		US 2012148578 A1 14-06-2012	
		US 2012156207 A1 21-06-2012	
		US 2012156220 A1 21-06-2012	
		WO 2008150494 A1 11-12-2008	